<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733040</url>
  </required_header>
  <id_info>
    <org_study_id>MOR202C205</org_study_id>
    <nct_id>NCT04733040</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)</brief_title>
  <acronym>NewPLACE</acronym>
  <official_title>A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MorphoSys AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-arm, multi-center, open-label, parallel-group phase II trial will assess the efficacy,&#xD;
      safety and pharmacokinetics/pharmacodynamics of the human antibody MOR202 in subjects with&#xD;
      anti-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After treatment, subjects will enter a repeat treatment period (3 months) if necessary; and a&#xD;
      final follow-up period of 15 to 18 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy: percent change of anti-PLA2R antibody levels</measure>
    <time_frame>3 months compared to baseline</time_frame>
    <description>efficacy of 2 different dosing regimens of MOR202 in subjects with anti-PLA2R antibody positive MN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy: immunological complete response (ICR) rate</measure>
    <time_frame>ICR rate at 3 months, 6 months, 12 months and 24 months</time_frame>
    <description>efficacy of 2 different dosing regimens of MOR202</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy: overall proteinuria response (OPR) rate</measure>
    <time_frame>OPR rate at 6 months, 12 months and 24 months.</time_frame>
    <description>efficacy of 2 different dosing regimens of MOR202</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety: determined by the frequency, incidence and severity of TEAEs</measure>
    <time_frame>through treatment completion, an average of 3 months per treatment period</time_frame>
    <description>frequency, incidence and severity of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>MOR202 serum concentrations after multiple i.v. administrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number of subjects developing anti-MOR202 antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Glomerulonephritis</condition>
  <condition>Membranous Nephropathy</condition>
  <condition>antiPLA2R Positive</condition>
  <arm_group>
    <arm_group_label>MOR202 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 doses administered on Day 1, 8, 15, 29, and 57</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOR202 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses administered on Day 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOR202</intervention_name>
    <description>5 or 2 doses of MOR202 will be administered as an intravenous infusion</description>
    <arm_group_label>MOR202 Arm 1</arm_group_label>
    <arm_group_label>MOR202 Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects &gt; 18 to &lt; 80 years (at date of signing the informed consent form [ICF]).&#xD;
&#xD;
          -  Urine protein to creatinine ratio (UPCR) of &gt; 3.0 g/g or proteinuria &gt; 3.5 g/24 h&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &gt; 50 ml/min/1.73 m² (eGFR &gt;30 and &lt; 50&#xD;
             ml/min/1.73 m² can be included provided an interstitial fibrosis and tubular atrophy&#xD;
             (IFTA) score of &lt; 25% in a kidney biopsy)&#xD;
&#xD;
          -  Not in spontaneous remission despite proper treatment with angiotensin-converting&#xD;
             enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) (sufficient dose and&#xD;
             treatment duration) as per clinical practice and scientific guidelines. If the subject&#xD;
             is intolerant to ACEI and ARBs, the reason must be documented and approval for&#xD;
             enrollment be obtained from the Medical Monitor.&#xD;
&#xD;
          -  Systolic blood pressure (BP) &lt;150 mmHg and diastolic BP &lt;100 mmHg after 5 minutes of&#xD;
             rest.&#xD;
&#xD;
          -  Serum anti-PLA2R antibodies &gt; 50.0 RU/mL determined by Euroimmun ELISA.&#xD;
&#xD;
          -  Female subjects: A female is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Not a female of childbearing potential (FCBP)&#xD;
&#xD;
               2. A FCBP who agrees to follow the contraceptive guidance during the treatment&#xD;
                  period and for at least 3 months after the last dose of MOR202&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin &lt; 80 g/L.&#xD;
&#xD;
          -  Thrombocytopenia: Platelets &lt; 100.0 x 109/L.&#xD;
&#xD;
          -  Neutropenia: Neutrophils &lt; 1.5 x 109/L.&#xD;
&#xD;
          -  Leukopenia: Leukocytes &lt; 3.0 x 109/L.&#xD;
&#xD;
          -  Hypogammaglobulinemia: Serum immunoglobulins ≤ 4.0 g/L.&#xD;
&#xD;
        Subjects may receive supportive therapies to meet the above criteria&#xD;
&#xD;
          -  B-cells &lt; 5 x 106/L&#xD;
&#xD;
          -  Diabetes mellitus type 2: Subjects with type 2 diabetes mellitus may only enter the&#xD;
             clinical trial if a kidney biopsy performed within 6 months prior to screening shows&#xD;
             MN without evidence of diabetic nephropathy and diabetes is controlled, as shown by:&#xD;
&#xD;
               1. Glycated hemoglobin (HbAlc) &lt;8.0 % or 64 mmol/mol.&#xD;
&#xD;
               2. No diabetic retinopathy known.&#xD;
&#xD;
               3. No peripheral neuropathy known.&#xD;
&#xD;
          -  Total bilirubin, aspartate aminotransferase or alanine aminotransferase &gt;1.5 x ULN,&#xD;
             alkaline phosphatase &gt;3.0 x ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Morphosys Clinical Program Lead</last_name>
    <phone>+498989927</phone>
    <phone_ext>0</phone_ext>
    <email>MOR202C205-CPL@morphosys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Managadze National Center of Urology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Heraklion Venizeleio-Papaneio</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JeJu National University Hospital</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Botkin Hospital Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gun Kaog Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kings College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham Renal and Transplant Unit</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Felzartamab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

